Skip to content

The effect of ingestion of fucoidan derived from Cladosiphon okamuranus on human NK cells.

The effect of ingestion of fucoidan derived from Cladosiphon okamuranus Tokida on human NK cells: A randomized, double-blind, placebo-controlled trial. - The effect of ingestion of fucoidan derived from Cladosiphon okamuranus Tokida on human NK cells: A randomized, double-blind, placebo-controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000043804
Enrollment
40
Registered
2021-04-03
Start date
2016-06-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

To ingest 3g / day of fucoidan food for 12 weeks To ingest Placebo food for 12 weeks

Sponsors

KSO Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy adult man and woman over 20 years old and under 65 years old 2) Persons who voluntarily agreed to participate in writing after understanding the purpose of the study

Exclusion criteria

Exclusion criteria: 1)Persons who have a serious disease, are undergoing treatment, have a medical history 2)Persons who have a chronic disease and regularly use drugs 3)Persons who regularly use supplements/health foods (including foods for specified health use and foods with functional claims) that may affect immunity 4)Persons who constantly drink more than proper drinking (500 mL per bottle of beer on average per day) 5)Persons who cannot stop drinking from 2 days before each test 6)Persons who have been declared to have allergies 7)Persons with a history of gastrointestinal diseases and gastrointestinal surgery 8)Persons who participants in trials using other foods, medicines and cosmetics 9)Persons who are pregnant, willing to become pregnant during the test period, or breastfeeding 10)Person who the doctor responsible for the study deems inappropriate as a subject

Design outcomes

Primary

MeasureTime frame
Evaluation of NK cell activity (from the start of ingestion to 12 weeks later)

Countries

Japan

Contacts

Public ContactMakoto Tomori

South Product Co., Ltd Research and development

m-tomori@south-p.co.jp098-982-1272

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026